How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?

Area of Science:

• Biophysics
• Virology
• Pharmacology

Background:

• Ion channel blockers are crucial in biomedicine and drug development.
• Influenza M2 channel blockers, amantadine and rimantadine, are vital anti-flu agents.
• Understanding drug resistance mechanisms is key to developing effective antivirals.

Purpose of the Study:

• To elucidate the blockage mechanism of the influenza M2 channel by amino-adamantyls.
• To investigate the molecular basis of M2 channel drug resistance.
• To inform the design of next-generation influenza therapeutics.

Main Methods:

• Computational analyses of channel-blocker interactions.
• Experimental verification of computational findings.
• Analysis of M2 channel mutations and their impact on drug resistance.

Main Results:

• Amino-adamantyls inhibit M2 H(+) channel activity through electrostatic hindrance from their charged amino group.
• The adamantyl group alone does not affect channel conductivity.
• Mutations create larger binding pockets in M2, allowing drug binding but maintaining channel function and conferring resistance.
• Drug mobility in mutated channels prevents electrostatic hindrance.

Conclusions:

• The positively charged amino group of amino-adamantyls is essential for M2 channel blockage.
• Drug resistance arises from mutations that increase binding pocket size, reducing drug efficacy.
• Insights gained can guide the development of novel anti-influenza drugs effective against resistant strains.